What is PMOS? The condition formerly known as PCOS — explained

If you've been searching for information about PCOS recently, you may have noticed it's increasingly being referred to as PMOS. This isn't a typo or a regional variation. In May 2026, a global consensus of medical and scientific organisations officially adopted a new name for the condition — and the change matters more than a rename usually does.

This guide explains what PMOS is, why the name changed, what the condition actually involves day to day, and what the research — including research specifically on the people who live alongside those with PMOS — tells us about being genuinely useful rather than well-intentioned but unhelpful.

What is PMOS?

PMOS stands for Polyendocrine Metabolic Ovarian Syndrome. It is one of the most common hormonal conditions affecting women of reproductive age. The landmark 2026 Lancet consensus paper confirmed it affects around 1 in 10 women worldwide — more than 170 million people — making it significantly more common than most people realise.¹

The condition involves a complex interaction of hormonal, metabolic, and reproductive factors. It is not simply a reproductive condition, and it is not simply a hormonal imbalance. It is a multisystem disorder that affects the endocrine system, metabolic function, mental health, skin, and fertility — often simultaneously, in varying combinations, with symptoms that differ significantly between individuals.

Why did the name change from PCOS to PMOS?

The rename followed an unprecedented global consensus process involving 56 leading academic, clinical, and patient organisations, drawing on surveys completed by over 14,000 patients and health professionals across multiple world regions. The process took over a decade to complete.¹

The old name — Polycystic Ovary Syndrome — had two significant problems. First, the "cysts" described are not pathological cysts. They are immature follicles — a different thing entirely — and the misnomer led to women being dismissed or misdiagnosed when their ultrasound looked clear. Second, the name focused entirely on the ovaries and said nothing about the broader endocrine and metabolic picture that defines the condition for many women.

The new name — Polyendocrine Metabolic Ovarian Syndrome — is more accurate. "Polyendocrine" reflects that multiple hormonal systems are involved. "Metabolic" captures the metabolic components, particularly insulin resistance, which is central to many cases. "Ovarian" keeps the connection to the ovaries without implying cysts must be present.

What causes PMOS?

The precise cause is not fully understood, but the current scientific consensus identifies a combination of genetic predisposition, hormonal dysregulation — particularly involving androgens (male hormones present in all women) and insulin — and immune and inflammatory factors.³

Insulin resistance is present in a significant proportion of women with PMOS, including those who are not overweight. When cells don't respond normally to insulin, the pancreas produces more of it. Higher insulin levels stimulate the ovaries to produce more androgens, which disrupts ovulation and drives many of the visible symptoms — acne, hair changes, irregular cycles. This is why diet and metabolic health are part of the clinical picture, and also why weight change is frequently both a symptom and a management target, though that framing carries its own complexity for the women living with it.

PMOS also has a heritable component — it tends to run in families, and first-degree relatives of women with the condition have a higher likelihood of having it themselves.³ It is not caused by diet, lifestyle choices, or stress, though those factors can influence severity.

What PMOS actually feels like

Because PMOS is a multisystem condition, its effects can touch many areas of daily life — not just periods and fertility. This matters for partners, because what looks like a collection of unrelated issues is often the same underlying condition expressing itself in different ways.

Common experiences include:

• Irregular, unpredictable, or absent periods — which creates a kind of background uncertainty that doesn't go away. Not knowing when the next period will arrive, or whether it will come at all, has a cumulative effect
• Fatigue that doesn't track with sleep — often driven by insulin resistance and the metabolic load of the condition, not by laziness or poor habits
• Mood changes and low mood — research consistently shows women with PMOS have more than 2.5 times the risk of depression compared to women without it, linked to the hormonal and metabolic dimensions of the condition rather than simply the psychological burden of having it⁴
• Skin and hair changes — acne driven by elevated androgens, and changes to body and facial hair. These are frequently distressing in ways that are easy to underestimate from the outside
• Weight changes or persistent difficulty managing weight despite genuine effort — this is a metabolic issue, not a motivational one. Insulin resistance makes weight management significantly harder, and comments about diet or exercise in this context are almost always unhelpful
• Brain fog and difficulty concentrating — underreported but consistently described by women with PMOS as one of its more disabling features
• Fertility challenges — PMOS is one of the most common causes of ovulatory infertility. Whether or not children are currently wanted, this knowledge carries its own weight

The diagnosis problem

Up to 70% of women with PMOS are estimated to remain undiagnosed.² The reasons are multiple: the condition presents differently in different people, there is no single diagnostic test, the old name led clinicians to rule it out when no cysts were visible on ultrasound, and — like most conditions primarily affecting women — it has historically received less research funding and clinical attention than its prevalence warrants.

The Lancet consensus paper itself identifies the old name as having contributed directly to delayed diagnosis, fragmented care, and stigma.¹ Women presenting with irregular periods, fatigue, low mood, and skin changes are frequently told each symptom is unrelated, prescribed treatments for individual symptoms rather than the underlying condition, and left to connect the dots themselves — often years later.

If the woman in your life has recently been diagnosed, or is currently trying to get answers, that journey may have been longer and more frustrating than it should have been. Understanding that context is part of understanding her.

How cycles are affected

For many women with PMOS, cycles are irregular — longer than average, unpredictable, or sometimes absent for months. This has practical implications for cycle awareness: predictions based on a standard 28-day cycle don't apply, and the hormonal rhythm that underpins mood and energy across the month is less regular too.

Yori accounts for this. Cycle estimates are built from logged period data rather than a fixed assumption, and early estimates are flagged as approximate. Over time, as more data is logged, the picture becomes clearer — even if it remains more variable than a typical cycle.

The more important point is this: if she seems to be in a harder stretch and the cycle picture doesn't clearly explain it, that is normal for PMOS. Her body is doing something more complex than a standard cycle. Working with that uncertainty — rather than trying to predict through it — is the more honest approach.

Treatment — what it involves and what it means for you

There is no cure for PMOS. Treatment addresses symptoms and reduces long-term health risks. Because the condition presents so differently between individuals, treatment is also highly individualised — what works well for one person may be irrelevant for another.

The main approaches include:

• Lifestyle intervention — diet and exercise changes that improve insulin sensitivity can meaningfully reduce symptoms for many women with PMOS. This is evidence-based and recommended as first-line. It is also genuinely hard to sustain for anyone, and harder still when fatigue and low mood are part of the condition itself. Supporting her efforts here means not adding pressure, not commenting on food choices, and not framing it as something she just needs to commit to
• Hormonal treatment — combined oral contraceptives are commonly prescribed to regulate cycles, manage acne, and reduce androgen effects. Progestins are used in women who can't or don't want oestrogen. These can cause side effects including mood changes, libido changes, and altered energy. If she seems different on hormonal treatment — emotionally, physically — the medication may be a factor worth acknowledging rather than a signal about the relationship
• Insulin-sensitising medication — metformin is commonly prescribed to address the insulin resistance component, particularly where metabolic symptoms are prominent or fertility is a concern. It can cause gastrointestinal side effects, especially initially
• Fertility treatment — where ovulation is irregular or absent, treatments to induce ovulation (clomifene, letrozole) or assisted conception (IVF) may be pursued. This is a significant undertaking emotionally and physically, for both of you

The impact on partners — what the research shows

Research specifically on partners of women with PMOS is limited compared to conditions like endometriosis, but the evidence that exists is consistent. The psychological burden of the condition on women is well-documented — including a more than 2.5-fold elevated risk of depression and substantially elevated rates of anxiety⁴ — and that burden doesn't exist in isolation from the people closest to them.

A systematic review and meta-synthesis published in 2026 found that PMOS significantly strains sexual and social functioning, with changes in appearance, mood, and fertility linked to reduced intimacy, lower self-esteem, and in severe cases, relationship breakdown.⁵ Infertility, where present, was identified as a major source of distress affecting both women and their partners. The research noted that societal expectations around femininity and motherhood compound the psychological weight of the condition — meaning what she carries is not only medical but social.

The 2025 international PMOS guidelines explicitly recommend that healthcare professionals assess and address psychological wellbeing as a core component of PMOS care, not an optional extra.⁶ In practice, many women still don't receive this. The partner is often the closest available source of consistent support — which is a significant role, particularly when the condition is chronic and its effects are variable.

The fertility conversation

PMOS is one of the most common causes of ovulatory infertility — the kind where eggs are not released regularly or at all. This doesn't mean everyone with PMOS has fertility problems; many conceive without difficulty, particularly with treatment. But the possibility sits in the background of the condition for anyone of reproductive age, whether or not it is currently relevant.

If fertility is something you're both thinking about, the treatment pathway is usually straightforward compared to other causes of infertility — ovulation induction with medication is effective for many women with PMOS. A specialist in reproductive medicine who understands PMOS specifically is the right starting point. What a partner can do in this space is largely about not adding pressure and being willing to hold uncertainty alongside her rather than requiring her to manage yours.

What she needs from you — and what she doesn't

There is no universal answer. PMOS is individual — its symptoms, severity, and daily experience vary considerably between people, and what helps varies too. What follows is grounded in what the evidence and the experience of women with PMOS consistently identifies. Ask her what she actually needs, and accept that her answer will change over time.

She needs to be believed. PMOS is frequently dismissed, minimised, or reduced to weight-loss advice. If she says she's exhausted, that her skin is affecting how she feels about herself, or that she can't lose weight despite genuine effort, believe her. The condition has a physiological basis. Her experience is not a motivation problem.

Don't optimise. Listen first. Arriving with research, supplements, dietary protocols, or treatment options she hasn't asked about is a common response from partners who want to help. Sometimes it's welcome. Often what's needed first is simply to be heard. Ask before you advise.

Understand the weight of unpredictability. Not knowing when the next period will arrive, whether a bad day is the condition or something else, or what the long-term picture looks like — that uncertainty is its own kind of exhaustion. Being patient with it, rather than asking for timelines or certainty she doesn't have, matters more than it might seem.

Don't comment on weight or food. Given the relationship between insulin resistance, metabolism, and weight in PMOS, comments about diet, exercise, or body are almost always counterproductive — even when sympathetically intended. This is an area to stay out of unless she specifically invites you in.

PMOS and Yori

Yori supports PMOS as one of its six dedicated conditions. When a profile is set up with PMOS, the daily AI insights adapt to reflect the irregular cycle patterns, the metabolic and energy-related dimensions of the condition, and the kind of support that tends to help on the harder days.

Yori updated its terminology to PMOS — with "formerly PCOS" shown alongside it — in line with the 2026 Lancet consensus. If you're using the app and see the new term, that's intentional and reflects the current scientific position.